Cerus Current Ratio 2010-2025 | CERS
Cerus current ratio from 2010 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Cerus Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-03-31 | $0.16B | $0.07B | 2.32 |
| 2024-12-31 | $0.15B | $0.06B | 2.39 |
| 2024-09-30 | $0.14B | $0.05B | 2.59 |
| 2024-06-30 | $0.14B | $0.05B | 2.51 |
| 2024-03-31 | $0.14B | $0.06B | 2.41 |
| 2023-12-31 | $0.14B | $0.07B | 2.14 |
| 2023-09-30 | $0.15B | $0.08B | 1.88 |
| 2023-06-30 | $0.15B | $0.08B | 2.01 |
| 2023-03-31 | $0.16B | $0.08B | 2.09 |
| 2022-12-31 | $0.17B | $0.12B | 1.45 |
| 2022-09-30 | $0.17B | $0.10B | 1.73 |
| 2022-06-30 | $0.17B | $0.08B | 2.08 |
| 2022-03-31 | $0.17B | $0.07B | 2.59 |
| 2021-12-31 | $0.19B | $0.08B | 2.38 |
| 2021-09-30 | $0.18B | $0.07B | 2.75 |
| 2021-06-30 | $0.19B | $0.07B | 2.82 |
| 2021-03-31 | $0.18B | $0.06B | 3.31 |
| 2020-12-31 | $0.18B | $0.06B | 3.06 |
| 2020-09-30 | $0.18B | $0.05B | 3.84 |
| 2020-06-30 | $0.18B | $0.04B | 4.15 |
| 2020-03-31 | $0.18B | $0.05B | 3.96 |
| 2019-12-31 | $0.13B | $0.05B | 2.55 |
| 2019-09-30 | $0.13B | $0.05B | 2.77 |
| 2019-06-30 | $0.14B | $0.05B | 2.68 |
| 2019-03-31 | $0.14B | $0.05B | 2.84 |
| 2018-12-31 | $0.15B | $0.05B | 2.79 |
| 2018-09-30 | $0.15B | $0.04B | 3.48 |
| 2018-06-30 | $0.14B | $0.03B | 5.03 |
| 2018-03-31 | $0.13B | $0.02B | 5.66 |
| 2017-12-31 | $0.09B | $0.02B | 3.89 |
| 2017-09-30 | $0.09B | $0.02B | 3.71 |
| 2017-06-30 | $0.07B | $0.03B | 2.94 |
| 2017-03-31 | $0.08B | $0.03B | 2.86 |
| 2016-12-31 | $0.09B | $0.03B | 3.50 |
| 2016-09-30 | $0.11B | $0.02B | 4.72 |
| 2016-06-30 | $0.11B | $0.03B | 4.36 |
| 2016-03-31 | $0.12B | $0.02B | 5.23 |
| 2015-12-31 | $0.13B | $0.02B | 5.97 |
| 2015-09-30 | $0.13B | $0.02B | 6.45 |
| 2015-06-30 | $0.14B | $0.02B | 6.50 |
| 2015-03-31 | $0.14B | $0.02B | 5.99 |
| 2014-12-31 | $0.08B | $0.03B | 2.57 |
| 2014-09-30 | $0.07B | $0.02B | 3.44 |
| 2014-06-30 | $0.07B | $0.02B | 3.24 |
| 2014-03-31 | $0.07B | $0.03B | 2.46 |
| 2013-12-31 | $0.08B | $0.04B | 1.98 |
| 2013-09-30 | $0.08B | $0.04B | 1.75 |
| 2013-06-30 | $0.08B | $0.03B | 2.95 |
| 2013-03-31 | $0.09B | $0.03B | 3.16 |
| 2012-12-31 | $0.04B | $0.03B | 1.72 |
| 2012-09-30 | $0.04B | $0.03B | 1.60 |
| 2012-06-30 | $0.04B | $0.02B | 1.80 |
| 2012-03-31 | $0.05B | $0.03B | 1.70 |
| 2011-12-31 | $0.04B | $0.02B | 1.88 |
| 2011-09-30 | $0.03B | $0.01B | 2.16 |
| 2011-06-30 | $0.03B | $0.02B | 1.49 |
| 2011-03-31 | $0.04B | $0.02B | 1.77 |
| 2010-12-31 | $0.04B | $0.02B | 2.12 |
| 2010-09-30 | $0.03B | $0.02B | 1.72 |
| 2010-06-30 | $0.03B | $0.01B | 2.07 |
| 2010-03-31 | $0.03B | $0.01B | 2.79 |
| 2009-12-31 | $0.03B | $0.01B | 2.51 |
| 2009-09-30 | $0.04B | $0.02B | 2.25 |
| 2009-06-30 | $0.03B | $0.01B | 2.33 |
| 2009-03-31 | $0.03B | $0.01B | 2.94 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.275B | $0.180B |
| Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $233.364B | 28.06 |
| Stryker (SYK) | United States | $146.969B | 30.73 |
| Boston Scientific (BSX) | United States | $146.968B | 36.79 |
| EssilorLuxottica (ESLOY) | France | $131.277B | 0.00 |
| Medtronic (MDT) | Ireland | $112.813B | 15.99 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.710B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.016B | 27.92 |
| ResMed (RMD) | United States | $37.047B | 27.83 |
| Agilent Technologies (A) | United States | $34.235B | 22.32 |
| GE HealthCare Technologies (GEHC) | United States | $33.847B | 16.07 |
| Terumo (TRUMY) | Japan | $26.946B | 35.00 |
| Koninklijke Philips (PHG) | Netherlands | $22.399B | 16.10 |
| Insulet (PODD) | United States | $21.023B | 82.52 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.780B | 12.06 |
| Baxter (BAX) | United States | $16.278B | 12.15 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.165B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.076B | 0.00 |
| Demant (WILYY) | Denmark | $8.854B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.273B | 21.83 |
| Lantheus Holdings (LNTH) | United States | $5.564B | 14.03 |
| Prestige Consumer Healthcare (PBH) | United States | $4.281B | 19.13 |
| Perrigo (PRGO) | Ireland | $3.794B | 9.62 |
| Haemonetics (HAE) | United States | $3.466B | 15.79 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.367B | 24.83 |
| Envista Holdings (NVST) | United States | $3.244B | 26.96 |
| GN Store Nord (GNNDY) | Denmark | $2.180B | 18.06 |
| QuidelOrtho (QDEL) | United States | $2.091B | 14.38 |
| LeMaitre Vascular (LMAT) | United States | $1.890B | 42.24 |
| AtriCure (ATRC) | United States | $1.653B | 0.00 |
| Acuren (TIC) | United States | $1.314B | 0.00 |
| Neogen (NEOG) | United States | $1.268B | 16.22 |
| AdaptHealth (AHCO) | United States | $1.190B | 12.08 |
| BioLife Solutions (BLFS) | United States | $1.136B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.063B | 23.91 |
| Kestra Medical Technologies (KMTS) | United States | $1.053B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.987B | 12.61 |
| InMode (INMD) | Israel | $0.920B | 9.27 |
| CeriBell (CBLL) | United States | $0.640B | 0.00 |
| Evolus (EOLS) | United States | $0.636B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.634B | 0.00 |
| Owens & Minor (OMI) | United States | $0.629B | 5.22 |
| Curaleaf Holdings (CURLF) | Canada | $0.565B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.550B | 0.00 |
| Valneva SE (VALN) | France | $0.535B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.422B | 0.00 |
| Surmodics (SRDX) | United States | $0.418B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.367B | 13.50 |
| SNDL (SNDL) | Canada | $0.347B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.334B | 59.50 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.283B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.276B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.273B | 23.00 |
| ZimVie (ZIMV) | United States | $0.266B | 12.09 |
| Sanara MedTech (SMTI) | United States | $0.265B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.264B | 0.00 |
| Quanterix (QTRX) | United States | $0.256B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.253B | 0.00 |
| Omeros (OMER) | United States | $0.227B | 0.00 |
| Biote (BTMD) | United States | $0.227B | 6.37 |
| OraSure Technologies (OSUR) | United States | $0.224B | 0.00 |
| Brainsway (BWAY) | Israel | $0.216B | 57.30 |
| TriSalus Life Sciences (TLSI) | United States | $0.211B | 0.00 |
| Organigram Global (OGI) | Canada | $0.191B | 0.00 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.186B | 15.16 |
| Verano Holdings (VRNOF) | United States | $0.180B | 0.00 |
| Exagen (XGN) | United States | $0.157B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.133B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.131B | 16.18 |
| MacroGenics (MGNX) | United States | $0.112B | 0.00 |
| Jin Medical (ZJYL) | China | $0.105B | 0.00 |
| Veru (VERU) | United States | $0.098B | 0.00 |
| Fonar (FONR) | United States | $0.092B | 11.88 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.090B | 0.00 |
| Agape ATP (ATPC) | $0.079B | 0.00 | |
| TerrAscend (TSNDF) | Canada | $0.074B | 0.00 |
| Apyx Medical (APYX) | United States | $0.069B | 0.00 |
| InterCure (INCR) | Israel | $0.067B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.066B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| ImmuCell (ICCC) | United States | $0.057B | 0.00 |
| Modular Medical (MODD) | United States | $0.045B | 0.00 |
| Nephros (NEPH) | United States | $0.041B | 55.43 |
| United-Guardian (UG) | United States | $0.037B | 12.94 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Safety Shot (SHOT) | United States | $0.020B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.017B | 0.00 |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |